P Sudre
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study
Boubaker K, Francioli P, Rickenbach M, Opravil M, Egger M, Bernasconi E, Chave J, Boggian K, Hirschel B, Haensel A, Furrer H, Sudre P, Flepp M, Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33:1931-7.
23.10.2001Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study
23.10.2001Clin Infect Dis 2001; 33:1931-7
Boubaker K, Francioli P, Rickenbach M, Opravil M, Egger M, Bernasconi E, Chave J P, Boggian Katia, Hirschel B, Haensel A, Furrer H, Sudre P, Flepp M, Telenti A
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA : the journal of the American Medical Association 1999; 282:2220-6.
15.12.1999AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
15.12.1999JAMA : the journal of the American Medical Association 1999; 282:2220-6
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza Pietro, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
Bassetti S, Bernasconi E, Vernazza P, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9.
01.06.1999Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
01.06.1999Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9
Bassetti S, Bernasconi E, Vernazza Pietro, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza P, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
13.03.1999Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
13.03.1999Lancet 1999; 353:863-8
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza Pietro, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
Rutschmann O, Perrin L, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:F71-7.
28.05.1998A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
28.05.1998AIDS (London, England) 1998; 12:F71-7
Rutschmann O T, Perrin L H, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H C, Vernazza Pietro, Malinverni R, Iten A, Opravil M, Hirschel B